Trending stocks today
Axsome Therapeutics (AXSM-Q)
NASDAQ:AXSM
90.17
4.20
(4.45%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
Experts are optimistic about Axsome Therapeutics' drug pipeline, particularly their lead depression drug in phase 3 trials and early trials for smoking cessation, migraine, and narcolepsy. The market is expressing increased interest in biotechs, with two analysts recently initiating coverage with positive ratings. Additionally, the company pre-announced positive sales on two key drugs last month, indicating positive momentum.
$91.450
No
- «
- ‹
- 1
- ›
- »
Axsome Therapeutics(AXSM-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Axsome Therapeutics(AXSM-Q) Frequently Asked Questions
What is Axsome Therapeutics stock symbol?
Axsome Therapeutics is a American stock, trading under the symbol AXSM-Q on the NASDAQ (AXSM). It is usually referred to as NASDAQ:AXSM or AXSM-Q
Is Axsome Therapeutics a buy or a sell?
In the last year, 1 stock analyst published opinions about AXSM-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Axsome Therapeutics.
Is Axsome Therapeutics a good investment or a top pick?
Axsome Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Axsome Therapeutics.
Why is Axsome Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Axsome Therapeutics worth watching?
In the last year, there was no coverage of Axsome Therapeutics published on Stockchase.
What is Axsome Therapeutics stock price?
On 2024-12-13, Axsome Therapeutics (AXSM-Q) stock closed at a price of $90.17.
They make drugs to treat the central nervous system, an area that rarely sees success. However, their drug pipeline looks promising. Their lead depression drug is in phase 3 trials, in early trials for smoking cessation, a migraine drug, and one for muscle weakness caused by narcolepsy. If all goes right, this stock could triple. Overall, the market is getting more interested in biotechs, and two analysts just started coverage (buy and outperform) on AXSM, based on their pipeline and cash flow. Last month, they pre-announced positive sales on two key drugs.